All In Biotech

Drug Trial Radar · NCT04964375

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

A Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

102

Actual

Start

Aug 31, 2021

Primary completion

Jul 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Abbisko Therapeutics Co, LtdIndustry
Sponsor type
Industry
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, Open-Label Study of ABSK043 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumor. Preliminary antitumor activity will also be assessed. Investigate the pharmacodynamics (PD) effects and Investigate the metabolites of oral ABSK043

Conditions

  • Neoplasms

Interventions

  • ABSK043 oral capsuleDrug

    ABSK043 is a novel, oral small molecule inhibitor of PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Incidence and Severity of AEsTime frame: Through study completion, an average of 6 months

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Sydney South West Private Hospital

    Liverpool, Australia

  • Icon Cancer Centre South Brisbane

    Brisbane, Queensland, Australia

  • Peninsula & South Eastern Haematology and Oncology Group

    Frankston, Victoria, Australia

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Fujian Cancer hospital

    Fuzhou, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • Mianyang Central Hospital

    Mianyang, China

  • Jiangsu Province Hospital

    Nanjing, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Shanghai Jiaotong University School of Medicine Ruijin Hospital

    Shanghai, China

  • Yuebei People's Hospital

    Shaoguan, China

  • Liaoning Cancer Hospital

    Shenyang, China

  • Renmin Hospital of Wuhan University

    Wuhan, China

  • Union Hospital Tongji Medical College Huazhong University of science and technology

    Wuhan, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi'an, China

  • Xiangyang Central Hospital

    Xiangyang, China

  • Yanbian University Hospital(Yanbian Hospital)

    Yanbian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.